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Muscle lipid oxidation is stimulated by peroxisome proliferator-activated receptor (PPAR) δ or adiponectin receptor signalling.
We studied human myocyte expression of the PPARδ and adiponectin receptor genes and their relationship to lipid parameters of
thedonors.ThemRNAlevels ofthethreeadiponectin receptors,AdipoR1,AdipoR2,and T-cadherin,were highlyinterrelated (r ≥
0.91). However, they were not associated with GPBAR1, an unrelated membrane receptor. In addition, the adiponectin receptors
were positively associated with PPARδ expression (r ≥ 0.7 5 ) .H o w e v e r ,t h e yw e r en o ta s s o c i a t e dw i t hP P A R α. Using stepwise
multiple linear regression analysis, PPARδ was a signiﬁcant determinant of T-cadherin (P = .0002). However, pharmacological
PPARδ activationdidnotincreaseT-cadherinexpression.ThemyocyteexpressionlevelsofAdipoR1andT-cadherinwereinversely
associatedwiththedonors’fastingplasmatriglycerides(P<. 03).Inconclusion,myocyteexpressionofPPARδ andtheadiponectin
receptors are highly coordinated, and this might be of relevance for human lipid metabolism in vivo.
1.Introduction
In states of increased circulating nonesteriﬁed fatty acids
(NEFA), such as fasting, high dietary fat intake, or obesity,
appropriate fatty acid oxidation by skeletal muscle and
liver is crucial to maintain insulin sensitivity and glucose
tolerance. Impairment of fatty acid oxidation, for example,
due to genetics, provokes increments in plasma NEFA levels,
ectopic lipid deposition in nonfat tissues, enhanced hepatic
VLDL production, and ﬁnally hyperlipidaemia [1]. Insulin
resistance, glucose intolerance, and type 2 diabetes may arise
from enhanced fatty acid signalling in skeletal muscle and
liver initiated by the elevated plasma NEFA levels per se or
by the accumulation of ectopic lipids [2].
Peroxisome proliferator-activated receptor (PPAR) δ,
a nuclear receptor and transcription factor, represents an
important regulator of fatty acid oxidation in rodent and
human skeletal muscle. PPARδ is activated by long-chain
NEFA and, in concert with coactivator proteins, such as
PPARγ coactivator 1, induces the expression of genes
involved in cellular fatty acid uptake, β-oxidation, and
energy uncoupling [3]. Alternatively, muscular fatty acid
oxidationisstimulatedbyadiponectin,aninsulin-sensitizing
adipokine negatively associated with adipose tissue mass.
Adiponectin signalling triggers phosphorylation and inac-
tivation of acetyl-CoA carboxylase promoting a decline in
cytosolic malonyl-CoA levels and, thereby, enhancing fatty
acyl-CoA import into mitochondria and β-oxidation [4, 5].
Thefunctionsofadiponectin aremediated viathreediﬀerent
receptors, that is, AdipoR1, AdipoR2, and T-cadherin, which
are abundant in skeletal muscle. AdipoR1 and AdipoR2 were
shown to bind trimeric full-length adiponectin as well as2 Experimental Diabetes Research
its proteolytically cleaved globular domain, while T-cadherin
binds hexameric and high-molecular-weight oligomeric
forms of adiponectin [6].
Whether the PPARδ and adiponectin receptor signalling
pathways are linked at any cellular level is currently un-
known. In this gene expression study, we therefore investi-
gated whether the expression of the genes encoding PPARδ
(PPARD) and the adiponectin receptors AdipoR1 (ADI-
POR1), AdipoR2 (ADIPOR2), and T-cadherin (CDH13)i s
interrelated. To this end, we used in vitro diﬀerentiated
human skeletal muscle cells (myotubes) from 39 young
and healthy human donors. Since basal gene expression of
human myotubes was previously shown to reﬂect in vivo
phenotypes of the donors [7–9], we furthermore assessed
whether these genes’ expression levels associate with in vivo
lipid parameters of the donors.
2.MaterialsandMethods
2.1. Cell Culture. Primary human skeletal muscle cells were
grown from satellite cells obtained from vastus lateralis
musclebiopsiesanddiﬀerentiatedtomyotubes,aspreviously
described [10]. Some myotube cultures were treated for 20h
either with 0.1% DMSO for carrier control or with 1μmol/L
of the PPARδ-speciﬁc agonist GW501516 (Alexis Biochemi-
cals, Gr¨ unberg, Germany).
2.2. Myotube Donors. The 39 donors were young and healthy
Caucasian participants of the T¨ ubingen family study for
type 2 diabetes and gave informed written consent to the
study. All individuals were metabolically characterised by
an oral glucose tolerance test, as described earlier [11]. The
subject characteristics are given in Table 1. The study was in
accordancewiththeprinciplesoftheDeclarationofHelsinki,
and the protocol was approved by the Ethics Committee of
the Medical Faculty of the University of T¨ ubingen.
2.3. Quantitative RT-PCR (qPCR). Myotubes were washed
with PBS and harvested by trypsinisation. RNA was isolated
with RNeasy columns (Qiagen, Hilden, Germany). Total
RNA treated with RNase-free DNase I was transcribed into
cDNA using AMV reverse transcriptase and the First Strand
cDNA kit from Roche Diagnostics (Mannheim, Germany).
qPCR was performed in triplicate with SYBR Green I dye
on a LightCycler (Roche Diagnostics, Mannheim, Germany).
The primers were purchased from TIB MOLBIOL (Berlin,
Germany): ADIPOR1 mRNA forward 5 -ATTGAGGTA-
CCAGCCAGATG-3 , reverse 5 -GAGGTCTATGACCAT-
GTAGC-3 ; ADIPOR2 mRNA forward 5 -GATTGTCAT-
CTGTGTGCTGG-3 , reverse 5 -CTGGAGACTGGTAGG-
TATCA-3 ; CDH13 mRNA forward 5 -TGCTGATAACCC-
TGGAGGAC-3 , reverse 5 -ATGGGCAGGTTGTAGTTT-
GC-3 ; GPBAR1 mRNA forward 5 -GCTGCTTCTTCC-
TGAGCCTAC-3 , reverse 5 -GTTGGGAGCCAAGTAGAC-
GAG-3 ; PPARD mRNA forward 5 -AAGAGGAAGTGG-
CAGAGGCA-3 , reverse 5 -TGCCACCAGCTTCTTCTT-
CT-3 ; PPARA mRNA forward 5 -CCATCGGCGAGGATA-
GTTCT-3 , reverse 5 -CTGCGGTCGCACTTGTCATA-3 ;
28S-rRNAforward5 -ACGGCGGGAGTAACTATGACT-3 ,
reverse 5 -CTTGGCTGTGGTTTCGCT-3 . The annealing
temperatures were ADIPOR1 mRNA −66◦C; ADIPOR2
mRNA∗−64◦C; CDH13 mRNA −66◦C; GPBAR1 mRNA
−68◦C; PPARD mRNA∗−67◦C; PPARA mRNA∗−67◦C;
28S-rRNA −63◦C. All reactions contained 4mmol/lMgCl2
(reactions marked with asterisk additionally contained 5%
DMSO) and were run for 45 cycles. Cellular mRNA contents
are given in fg mRNA (or rRNA)/μg total RNA. The basal
expression levels are given in Table 1. Furthermore, we per-
formed probe-based qPCR (LightCycler, Roche Diagnostics)
using probes from the Universal ProbeLibrary (Roche Diag-
nostics) and primers from TIB MOLBIOL to determine the
mRNA expression levels of ADIPOR1, ADIPOR2, CDH13,
PPARD, UCP3, TFAM, PPARGC1A, and the housekeeping
gene RPS13 (primer sequences and PCR conditions can be
provided upon request).
2.4. Oral Glucose Tolerance Test (OGTT) and Hyperinsulinae-
mic-EuglycaemicClamp. Bothprocedureswereperformedas
previously described in detail [11].
2.5. Laboratory Measurements. Glucose was determined
using a bedside glucose analyzer (Yellow Springs Instru-
ments,YellowSprings,OH,USA).Insulinwasdeterminedby
a microparticle enzyme immunoassay (Abbott Laboratories,
Tokyo,Japan).NEFAandglycerolweremeasuredusingenzy-
matic assays from WAKO Chemicals (Neuss, Germany) and
Sigma (Deisenhofen, Germany), respectively. Triglycerides,
total, HDL, and LDL cholesterol were determined with stan-
dard colorimetric methods using a Roche/Hitachi analyzer
(RocheDiagnostics,Mannheim,Germany).Adiponectinwas
determined by a radioimmunoassay (Linco Research, St.
Charles, MO, USA).
2.6. Selection and Genotyping of Single Nucleotide Polymor-
phisms(SNPs). Tostudytheinﬂuenceofgeneticvariationon
PPARD, ADIPOR1, ADIPOR2,a n dCDH13 expression, we
selected the unlinked PPARD SNPs rs2267668 A/G (intron
2) and rs1053049 T/C (3 -untranslated region) and the
ADIPOR1 promoter SNP rs6666089 for which we previously
reported in vivo functionality [11–13]. For genotyping,
DNA was isolated from whole blood using a commercial
DNA isolation kit (NucleoSpin, Macherey & Nagel, D¨ uren,
Germany). Genotyping was performed with TaqMan assays
(Applied Biosystems, Foster City, CA, USA). All SNPs passed
the quality controls. Details on this as well as on minor allele
frequencies, genotyping success rates, and Hardy-Weinberg
equilibrium are reported in the aforementioned references.
2.7. Statistics. To approximate normal distribution, all data
wereloge transformedpriortostatisticalanalysis.Two-group
comparisonswereperformedusingunpairedStudent’st-test.
To adjust the dependent variable for confounding variables,
multiple linear regression models were used (standard least
squaresmethod).Stepwisemultiplelinearregressionanalysis
was performed to identify the best predictor for the depen-
dent variable. A P value <.05 was considered statisticallyExperimental Diabetes Research 3
Table 1: Clinical characteristics and myotube gene expression data of the donors (N = 39).
Parameter Women Men P1 P2
N 18 21 — —
Age (y) 28 ±72 5 ±4. 1 2 —
BMI (kg/m2)2 4 .1 ±4.02 2 .8 ±2.9. 2 . 5
Body fat (%) 27 ±81 8 ±6 .0002 .0006
Waist-hip ratio 0.79 ±0.09 0.84 ±0.05 .0155 .0006
Fasting plasma glucose (mM) 4.75 ±0.40 4.76 ±0.47 1.0 .8
120-min plasma glucose (mM) 5.24 ±1.25 5.40 ±1.15 .6 .5
ADIPOR1 mRNA 369 ±198 343 ±185 1.0 —
ADIPOR2 mRNA 149 ±75 131 ±64 .7 —
CDH13 mRNA 601 ±324 537 ±295 .8 —
GPBAR1 mRNA 3.16 ±0.94 2.68 ±0.70 .16 —
PPARD mRNA 81.8 ±40.28 4 .6 ±38.4. 8 —
PPARA mRNA 47.8 ±11.04 9 .0 ±8.5. 6 —
28S-rRNA 2.70 ±1.19 ×106 2.61 ±1.18 ×106 .9 —
Data are given as means ± SD. Gene expression data are given in fg mRNA (or rRNA)/μg total RNA. Statistical analysis was performed after ln-transformation
of the data. P1: unadjusted P values (Student’s t-test); P2: P values after adjustment (multiple linear regression analysis): BMI, body fat, and waist-hip ratio
were adjusted for age; plasma glucose concentrations were adjusted for age and body fat.
signiﬁcant. The statistical software package JMP 4.0 (SAS
Institute, Cary, NC, USA) was used.
3. Results
The basal myotube mRNA expression levels were CDH13 >
ADIPOR1 > ADIPOR2 > PPARD (Table 1). No signiﬁcant
diﬀerences were seen in PPARD, ADIPOR1, ADIPOR2,o r
CDH13 mRNA levels between myotubes from male versus
female donors (Table 1).
Usingbivariateregressionanalysis,themRNAexpression
levels of all three adiponectin receptors, each normalised for
the housekeeping gene 28S-rRNA, were highly interrelated
(allr ≥0.91,allP<. 0001).Sinceboththedependentandthe
independentvariablewerenormalisedfor28S-rRNAinthese
initial analyses, these unusually strong correlations could,
theoretically,havereﬂectedthecorrelationof28S-rRNAwith
itself. To avoid this bias, we no longer normalised the mRNA
levelsfor28S-rRNAbutadjustedthemRNAlevelsofthegene
selected as dependent variable for 28S-rRNA using multiple
linear regression models. As presented in Figures 1(a)–1(c),
the strong correlations between the adiponectin receptors
remained unaﬀected by this procedure. This strengthens the
observation that the basal expression of all three adiponectin
receptors in human myotubes is highly coordinated. For
additional control, we studied the association between the
three adiponectin receptors and GPBAR1 encoding the
unrelated membrane-type bile acid receptor known to be
expressedin skeletal muscle.Afteradjustment for28S-rRNA,
noneoftheadiponectinreceptorswassigniﬁcantlycorrelated
with GPBAR1 (all P ≥ .2).
Then, we analysed the association between the adi-
ponectin receptors and PPARD. After adjustment for 28S-
rRNA, the mRNA levels of all three adiponectin receptors
were strongly correlated with PPARD expression (Figures
1(d)–1(f)). A similar association between the adiponectin
receptors and PPARA which encodes PPARα, the second
PPAR family member with pro-oxidative properties and of
importance in muscle, was not found (all P ≥ .2). This
underscores the speciﬁcity of the association between the
adiponectin receptors and PPARD at the gene expression
level.
To further strengthen the relationship between the adi-
ponectin receptor and PPARδ genes, we analysed these
genes’ expression levels according to SNPs in PPARD and
ADIPOR1. As depicted in Figure 2, homo- and heterozygous
carriers of the minor allele of ADIPOR1 SNP rs6666089
(dominant model) revealed signiﬁcantly reduced expression
levels of ADIPOR1 (P = .0317) and CDH13 (P = .0349)
a n dt e n d e dt oa s s o c i a t ew i t hr e d u c e dPPARD (P = .06; P
for trend in the additive model = .0242) and ADIPOR2 (P =
.1; P for trend in the additive model = .0284) expression.
Heterozygous minor allele carriers of PPARD SNP rs1053049
(homozygous carriers of the minor allele were absent in
this small group) showed signiﬁcantly higher expression
of PPARD (P = .0048), ADIPOR2 (P = .0207), and
CDH13 (P = .0334) and tended to associate with elevated
expression of ADIPOR1 (P = .06) as presented in (Figure 3).
PPARD SNP rs2267668 had markedly weaker eﬀects and,
thus, revealed signiﬁcant association with PPARD expression
only (P = .0258) (data not shown). These results support
the idea that the expression of the adiponectin receptor and
PPARδ genes is highly coordinated.
Using stepwise multiple linear regression analysis, we
observed that PPARD is, independently of the other genes,
a signiﬁcant determinant of CDH13 (P = .0002), but not
of ADIPOR1 or ADIPOR2 (both P>. 05). This suggested
thatCDH13representsanovelPPARδ targetgene.Toaddress
this issue, myotubes were treated for 20h with the PPARδ-
speciﬁc agonist GW501516 (1μmol/l) and DMSO (0.1%)
for carrier control. However, GW501516 treatment did not
signiﬁcantlyincrease CDH13mRNAexpressionascompared4 Experimental Diabetes Research
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Figure 1: Correlations between ADIPOR1, ADIPOR2, CDH13,a n dPPARD mRNA contents of skeletal muscle cells from 39 human donors
(N = 39). To approximate normal distribution, all data were loge transformed prior to statistical analysis. The dependent variable was
adjusted for 28S-rRNA using multiple linear regression models.
to DMSO (P = .8, n = 16), whereas it increased the ex-
pression of the described PPARδ target genes PDK4 and
ANGPTL4 (for data, see [9]).
To assess whether the highly coordinated expression of
PPARD and the adiponectin receptor genes—all located on
diﬀerent chromosomes—is caused by a common regulatory
miRNA, we screened the miRBase Targets database, Release
Version v5 (at http://microrna.sanger.ac.uk/targets/v5/), for
common miRNA binding sites in the four genes. In ADI-
POR2, only one putative binding site was identiﬁed, namely,
for miRNA-617. The other genes, however, did not reveal
any bona ﬁde binding site for miRNA-617. Thus, miRNAs
are improbable to represent the unifying link between these
genes. To approach whether the genes are under the control
of a common transcription factor, we performed in silico
analyses of the sequences spanning from 3kb upstream to
1kb downstream of the transcription initiation sites. Using
AliBaba 2.1 (at http://www.gene-regulation.com/pub/pro-
grams/alibaba2/index.html?), PROMO 3.0 (at http://alggen.
lsi.upc.es/cgi-bin/promo v3/promo/promoinit.cgi?dirDB=
TF 8.3/,MA T CH1.0(athttp://www.gene-regulation.com/cgi-
bin/pub/programs/match/bin/match.cgi/),andP-MATCH1.0Experimental Diabetes Research 5
P = .0317
rs6666089
GG XA
0
1
2
3
N
o
r
m
.
A
D
I
P
O
R
1
m
R
N
A
(
A
U
,
l
o
g
e
-
s
c
a
l
e
)
(a)
P = .1
rs6666089
GG XA
0
1
2
3
N
o
r
m
.
A
D
I
P
O
R
2
m
R
N
A
(
A
U
,
l
o
g
e
-
s
c
a
l
e
)
(b)
rs6666089
GG XA
P = .0349
0
0.5
1
1.5
2
N
o
r
m
.
C
D
H
1
3
m
R
N
A
(
A
U
,
l
o
g
e
-
s
c
a
l
e
)
(c)
rs6666089
GG XA
P = .06
0
1
2
3
N
o
r
m
.
P
P
A
R
D
m
R
N
A
(
A
U
,
l
o
g
e
-
s
c
a
l
e
)
(d)
Figure 2: Impact of the ADIPOR1 promoter SNP rs6666089 on ADIPOR1, ADIPOR2, CDH13,a n dPPARD mRNA contents of human
skeletal muscle cells. mRNA data were normalised for 28S-rRNA and are given in arbitrary units (AUs). To approximate normal distribution,
mRNA data were loge transformed prior to statistical analysis. The rs6666089 genotype was determined by TaqMan assay. Since there were
only two homozygous carriers of the A-allele among the muscle cell donors, we joined them with the heterozygous subjects to form the “XA”
group. Data are presented as means + SE.
(at http://www.gene-regulation.com/cgi-bin/pub/programs/
match/bin/match.cgi/), andP-MATCH1.0(athttp://www.gene
-regulation.com/cgi-bin/pub/programs/pmatch/bin/p-match
.cgi/) freeware for prediction of transcription factor binding
sites, we identiﬁed three transcription factors, that is, signal
transducer and activator of transcription 5A, speciﬁcity pro-
tein 1, and CCAAT/enhancer-binding protein α,w i t hp u t a -
tive binding sites in all four gene sequences. RNA inter-
ference-mediated knockdown of these candidates in C2C12
myocytes did however not aﬀect the expression of PPARD
or the adiponectin receptor genes (data not shown). Addi-
tionally, we knocked down FoxO1, one of the known tran-
scriptional regulators of the murine Adipor1 and Adipor2
genes [14]. This manipulation did however not aﬀect the ex-
pression of the adiponectin receptor and PPARδ genes either
(data not shown). Thus, the common upstream regulatory
mechanism remains elusive.
Since both adiponectin and PPARδ signalling regulate
muscle metabolism and mitochondrial biogenesis, we inves-
tigated whether the expression of genes crucially involved in
these processes, that is, PPARGC1A (encoding PPARγ coac-
tivator 1α), UCP3 (encoding uncoupling protein 3), and
TFAM (encoding mitochondrial transcription factor A), is
correlated with the expression of ADIPOR1, ADIPOR2,
CDH13,a n dPPARD. After adjustment for the housekeeping
gene,wefoundsigniﬁcantassociationsofADIPOR1,CDH13,
and PPARD expression levels with PPARGC1A, UCP3,a n d
TFAM (all P<. 045). ADIPOR2 was signiﬁcantly associated
with TFAM only (P = .007). This strengthens the role of
these receptors in mitochondrial oxidative metabolism.
Finally, we assessed whether the basal myotube expres-
sion levels of PPARD and the adiponectin receptor genes are
of relevance in vivo and reﬂect fasting plasma lipid parame-
ters of the myotube donors. After adjustment for gender, age,6 Experimental Diabetes Research
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Figure 3:ImpactofPPARDSNPrs1053049,locatedinthe3 -untranslatedregionofthegene,onPPARD,ADIPOR1,ADIPOR2,andCDH13
mRNA contents of the human skeletal muscle cells. mRNA data were normalised for 28S-rRNA and are given in arbitrary units (AUs). To
approximate normal distribution, mRNA data were loge transformed prior to statistical analysis. The rs1053049 genotype was determined
by TaqMan assay. There were no homozygous C-allele carriers among the muscle cell donors. Data are presented as means + SE.
and BMI, the fasting plasma triglyceride concentrations were
inversely associated with the ADIPOR1 and CDH13 mRNA
contents normalised for 28S-rRNA (Figures 4(a) and 4(c)).
Moreover, even though not signiﬁcant, the ADIPOR2 and
PPARD mRNA contents tended to inversely associate with
plasma triglycerides (Figures 4(b) and 4(d)). No signiﬁcant
associations were detected with fasting plasma NEFA, glyc-
erol, total-, HDL-, or LDL-cholesterol concentrations (all
P>. 1).
In addition, we assessed these genes’ association with in
vivo parameters of glucose metabolism. However, we did not
detect any signiﬁcant association of PPARD and adiponectin
receptors expression with fasting insulin concentrations (all
P ≥ .3), fasting and 120-min glucose concentrations (all P ≥
.3),orwithinsulinsensitivityindicesderivedfromtheOGTT
and the hyperinsulinaemic-euglycaemic clamp (all P>. 5),
respectively. Serum adiponectin levels did not associate with
the expression of PPARD, ADIPOR1, ADIPOR2,o rCDH13
either (all P ≥ .3).
4. Discussion
In this study, we could demonstrate, also by assessing SNP
eﬀects, that two signalling pathways known to mediate lipid-
burning and formerly considered independent, that is, the
PPARδ and the adiponectin pathway, are closely linked at
the gene expression level. The most obvious mechanism pos-
sibly underlying this phenomenon, that is, transcriptional
regulation of the adiponectin receptor genes by PPARδ,
could be excluded since PPARδ activation using a speciﬁc
and well-described pharmacological agonist had no eﬀect
on adiponectin receptor expression. Therefore, we assessed
other conceivable upstream regulatory factors. Using RNA
interference, transcription factors identiﬁed as putative can-
didatesforbindingtoallfourpromoters,suchassignaltrans-
ducer and activator of transcription 5A, speciﬁcity protein
1, and CCAAT/enhancer-binding protein α, turned out not
to be involved in this highly coordinated gene regulation,
neither did FoxO1, a known transcription factor regulatingExperimental Diabetes Research 7
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Figure 4: Association of myotube ADIPOR1, ADIPOR2, CDH13,a n dPPARD mRNA contents with fasting plasma triglyceride concentra-
tions of the 39 human donors (N = 39). mRNA data were normalised for 28S-rRNA and are given in arbitrary units (AUs). To approximate
normal distribution, all data were loge transformed prior to statistical analysis. Plasma triglycerides were adjusted for gender, age, and BMI
using multiple linear regression models.
the murine Adipor1 and Adipor2 genes. miRNAs targeting
all four genes could also not be identiﬁed. Thus, the unify-
ing regulatory mechanism responsible for our observation
remains to be uncovered in further studies addressing other,
for example, epigenetic mechanisms (DNA methylation,
histone modiﬁcation, and nucleosome positioning).
Most importantly, we could demonstrate that myotube
expression of PPARDandtheadiponectinreceptorsinversely
reﬂects the fasting plasma triglyceride concentration of the
donors. There may be two explanations to this: either circu-
lating triglycerides via their products of lipolytic breakdown,
that is, via NEFA, aﬀect the expression of PPARD and the
adiponectin receptor genes or increased expression of these
genes reduces the plasma triglyceride concentration. At least
for PPARD, we were recently able to show that, with the
only exception of stearate, no long-chain fatty acid is able to
change its expression [9]. Thus, an inﬂuence of triglyceride-
derived NEFA on these genes’ coordinated expression
appears less plausible. Instead, it is well known that the
adiponectinandPPARδ pathwaysstimulateβ-oxidationand,
inthisway,mayreducetheplasmatriglycerideconcentration
of the donors. Since plasma triglycerides are a well-known
readout of the hepatic lipid load [15], this association is
in line with the observation that an impairment of fatty
acid oxidation provokes increments in plasma NEFA levels,
ectopic lipid deposition in nonfat tissues, and enhanced
hepatic VLDL production [1] and underscores the idea of
a muscle-liver axis with muscle fatty acid oxidation being
an important determinant of hepatic lipid storage. In this
context,metabolicsignalsfromβ-oxidation(acyl-carnitines)
or muscle-derived humoral mediators (myokines) may
represent interesting candidate mediators of muscle-liver8 Experimental Diabetes Research
crosstalk.Finally, this translational ﬁnding provides evidence
that our in vitro data are of relevance for humans in vivo and
may explain the biological variance between individuals in
t e r m so fg o o dv e r s u sb a df a tb u r n e r s .
5. Conclusions
Expression of PPARD, ADIPOR1, ADIPOR2,a n dCDH13 in
human skeletal muscle cells is highly coordinated, and this
might be of relevance for human lipid metabolism in vivo,
as reﬂected by these genes’ consistent inverse association
with plasma triglycerides. Thus, the upstream regulatory
factor(s) responsible for this coordinated gene expression
could represent promising future targets for the control of
circulating lipids and hepatic fat load.
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